Contravir Pharmaceut (NASDAQ:CTRV) shares traded 5.08% up during most recent session to reach at the closing price of $0.62. The stock exchanged hands 1.49 Million shares versus average trading capacity of 1.06 Million shares, yielding a market cap of $47.23 Million. Wall Street analysts covering the stock are projecting that the stock will reach $6 within the next 52-weeks. The mean target projections are based on 1 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Contravir Pharmaceut (NASDAQ:CTRV) high price target of $6 and with a conservative view have low price target of $6.

Maxim Group “Initiates Coverage on” Contravir Pharmaceut (NASDAQ:CTRV) in a research note issued to investors on 5/06/16 to Buy.

On the other hand the company has Relative Strength Index (RSI 14) of 55.85 along with Average True Range (ATR 14) of 0.04, Consequently Contravir Pharmaceut (NASDAQ:CTRV)’s weekly and monthly volatility is 8.72%, 7.07% respectively. The company’s beta value is at 1.44.

In terms of Buy, Sell or Hold recommendations, Contravir Pharmaceut (NASDAQ:CTRV) has analysts’ mean recommendation of 2. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Contravir Pharmaceut (NASDAQ:CTRV)’s minimum EPS for the current quarter is at $-0.1 and can go high up to $-0.09. The consensus mean EPS for the current quarter is at $-0.1 derived from a total of 2 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.17 earnings per share for the same quarter during last year.

Previously Contravir Pharmaceut (NASDAQ:CTRV) reported $-0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.13 by $0.01. The company posted an earnings surprise of 7.7%.

Currently Contravir Pharmaceut (NASDAQ:CTRV)’s shares owned by insiders are 0.5%, whereas shares owned by institutional owners are 6.7%. However the six-month change in the insider ownership was recorded 5.54%, as well as three-month change in the institutional ownership was recorded -0.2%.

Contravir Pharmaceut (NASDAQ:CTRV) 52-week high price stands at $2.65 and low price stands at $0.53, its price distance from 52-week high is -76.6% while its distance from 52-week low price is 16.76%. The stock hit its 52-week high on 10/17/16, and 52-week low on 07/10/17.

Contravir Pharmaceut (NASDAQ:CTRV)’s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0. Its book value per share for the most recent quarter is $-0.02 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.08, however its price to cash per share ratio for the same period is 7.74. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.